Medical device company Artivion (NYSE:AORT) will be announcing earnings results this Thursday afternoon. Here’s what you need to know.
Artivion beat analysts’ revenue expectations by 4.2% last quarter, reporting revenues of $98.98 million, up 1.6% year on year. It was an exceptional quarter for the company, with an impressive beat of analysts’ sales volume estimates and an impressive beat of analysts’ EPS estimates.
Is Artivion a buy or sell going into earnings? Read our full analysis here, it’s free.
This quarter, analysts are expecting Artivion’s revenue to grow 10.4% year on year to $108.2 million, in line with the 9.8% increase it recorded in the same quarter last year. Adjusted earnings are expected to come in at $0.13 per share.
The majority of analysts covering the company have reconfirmed their estimates over the last 30 days, suggesting they anticipate the business to stay the course heading into earnings. Artivion has only missed Wall Street’s revenue estimates once over the last two years, exceeding top-line expectations by 2.6% on average.
Looking at Artivion’s peers in the healthcare equipment and supplies segment, some have already reported their Q2 results, giving us a hint as to what we can expect. Merit Medical Systems delivered year-on-year revenue growth of 13.2%, beating analysts’ expectations by 2.4%, and Penumbra reported revenues up 13.4%, topping estimates by 3.7%. Merit Medical Systems traded up 2.4% following the results while Penumbra was also up 11.9%.
Read our full analysis of Merit Medical Systems’s results here and Penumbra’s results here.
Debates around the economy’s health and the impact of potential tariffs and corporate tax cuts have caused much uncertainty in 2025. While some of the healthcare equipment and supplies stocks have shown solid performance in this choppy environment, the group has generally underperformed, with share prices down 3.1% on average over the last month. Artivion is up 3.7% during the same time and is heading into earnings with an average analyst price target of $32.71 (compared to the current share price of $31.40).
Unless you’ve been living under a rock, it should be obvious by now that generative AI is going to have a huge impact on how large corporations do business. While Nvidia and AMD are trading close to all-time highs, we prefer a lesser-known (but still profitable) semiconductor stock benefiting from the rise of AI. Click here to access our free report on our favorite semiconductor growth story.
StockStory is growing and hiring equity analyst and marketing roles. Are you a 0 to 1 builder passionate about the markets and AI? See the open roles here.